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Abstract
Background: Hereditary spastic paraplegia defines a group of genetically heterogeneous diseases characterized by
weakness and spasticity of the lower limbs owing to retrograde degeneration of corticospinal axons. One autosomal
recessive form of the disease is caused by mutation in the SPG7 gene. Paraplegin, the product of SPG7, is a component of
the m-AAA protease, a high molecular weight complex that resides in the mitochondrial inner membrane, and performs
crucial quality control and biogenesis functions in mitochondria.
Principal Findings: Here we show the existence in the mouse of a novel isoform of paraplegin, which we name paraplegin-
2, encoded by alternative splicing of Spg7 through usage of an alternative first exon. Paraplegin-2 lacks the mitochondrial
targeting sequence, and is identical to the mature mitochondrial protein. Remarkably, paraplegin-2 is targeted to the
endoplasmic reticulum. We find that paraplegin-2 exposes the catalytic domains to the lumen of the endoplasmic reticulum.
Moreover, endogenous paraplegin-2 accumulates in microsomal fractions prepared from mouse brain and retina. Finally, we
show that the previously generated mouse model of Spg7-linked hereditary spastic paraplegia is an isoform-specific knock-
out, in which mitochondrial paraplegin is specifically ablated, while expression of paraplegin-2 is retained.
Conclusions/Significance: These data suggest a possible additional role of AAA proteases outside mitochondria and open
the question of their implication in neurodegeneration.
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Introduction
Hereditary Spastic Paraplegias (HSPs) are genetically heteroge-
neous diseases characterized by progressive spasticity and
weakness of the lower limbs owing to retrograde degeneration of
cortical motor neuron axons [1]. The age at onset is variable,
ranging from early childhood to 70 years of age. More than 20
proteins involved in HSP have been so far identified, and their
functional studies begin to shed light on pathogenic pathways [2].
The identification of HSP patients carrying mutations in the
mitochondrial protease paraplegin and in the chaperone HSP60
has established disturbances of mitochondrial protein quality
control pathways as one of the pathogenic mechanisms in this
disease [3,4].
Paraplegin is the product of the SPG7 gene, mutations in which
cause about 4% of recessive familial cases of HSP and up to 12%
of sporadic cases [5,6,7]. Paraplegin contains an N-terminal
mitochondrial targeting sequence (MTS), two transmembrane
domains, a AAA (ATPase Associated with various cellular
Activities) domain and a C-terminal metal-dependent proteolytic
domain. Paraplegin is a subunit of the m-AAA (matrix-AAA)
protease, a key component of a quality control system that
conducts the surveillance of proteins of the inner membrane of
mitochondria by degrading in a selective manner non-assembled
and damaged polypeptides [8]. Moreover, the m-AAA protease
mediates proteolytic maturation of specific substrates, such as the
mitochondrial ribosomal component MrpL32 [9]. To form a
functional m-AAA protease, paraplegin assembles with the
homologous subunits AFG3L2 or AFG3L1 into a hetero-
oligomeric hexameric complex embedded in the inner mitochon-
drial membrane [10,11]. In contrast, AFG3L2 and AFG3L1 are
also able to form functional homo-oligomers [11]. Notably, two
different neurodegenerative diseases, an autosomal dominant form
of spinocerebellar ataxia and a recessive early onset spastic-ataxia
neuropathy syndrome, have been recently linked to mutations in
AFG3L2 [12,13]. AFG3L1 is a pseudogene in human, but it is
expressed in the mouse [14].
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36337Several pathogenic mutations, leading to loss-of-function of the
protein, have been reported in SPG7 [5,6,7]. To model the disease
in the mouse, we previously inactivated the gene by homologous
recombination by deleting the first two exons [15]. These exons
contain the starting methionine and the mitochondrial targeting
sequence. Lack of paraplegin expression was demonstrated in
mitochondrial fractions of the knock-out mice. These mice
reproduced the HSP phenotype, showing progressive motor
impairment from 4.5 months of age, and retrograde axonal
degeneration in long descending motor spinal tracts, long
ascending sensory spinal tracts, peripheral and optic nerves.
Moreover, ultrastructural analyses revealed the early appearance
of morphologically abnormal mitochondria in affected axons,
alterations that become more pronounced with aging [15].
Intramuscular delivering of Spg7 cDNA through AAV vectors in
knock-out mice stopped the progression of neuropathological
changes and rescued the mitochondrial morphology [16].
Here, we report the characterisation of a novel splicing isoform
of the murine Spg7 gene that includes an upstream, alternative first
exon. This transcript encodes a novel paraplegin isoform, which
we name paraplegin-2 that does not possess the MTS and localizes
to the endoplasmic reticulum (ER). The identification of
endogenous paraplegin-2 in mouse potentially points to new roles
of AAA proteases outside mitochondria and to novel aspects in
HSP pathogenesis.
Results
An alternative isoform of mouse paraplegin localises to
the endoplasmic reticulum
Searches of murine ESTs and cDNAs corresponding to murine
Spg7 in public databases identify several clones containing an
alternative first exon (exon 1b) located approximately 2.5 kb
upstream of the previously described exon 1 (Fig. 1A, B). A
complete cDNA (BC055488) and six different ESTs are detected
containing exon 1b spliced to either exon 2 or 3 (Fig. 1A). Since
exon 1b does not contain any in frame AUG, in both cases the first
in frame AUG lies in exon 3, predicting the translation of a shorter
paraplegin isoform lacking the first 105 amino acids (dubbed
paraplegin-2) (Fig. 1B). Remarkably, all the clones containing exon
1b derive from eye and retina libraries at different developmental
stages (Table S1).
We analysed the expression of these alternative splicing isoforms
using a RT-PCR approach (Figure 1C). Our results suggest that
alternative splicing of Spg7 comprising exon 1b occurs in all
analysed tissues, but the ratio between the splicing ex1b-2 and
ex1b-3 presents some tissue variability. Notably the eye shows a
strong amplification signal for both the alternative splicing
variants.
Paraplegin is targeted to mitochondria via a MTS encoded by
exons 1 and 2. Consistently, prediction of the subcellular
localization of paraplegin-2 using the software Mitoprot II returns
very low probabilities of mitochondrial targeting. To analyse the
subcellular localization of paraplegin-2, we transfected mouse
embryonic fibroblasts (MEFs), and NSC34 cells with the
BC055488 clone and performed an immunofluorescence assay
using a specific a-paraplegin antibody (V61) [15] (Figure 2 and
S1). As expected, paraplegin-2 does not target to mitochondria,
but assumes a reticular pattern of expression suggesting that it may
localise to membranes of the secretory pathway (Fig. 2, D–F).
Indeed, we found co-localization between paraplegin-2 signals and
ER markers, as an ER-targeted GFP [17], atlastin-1, or seipin
(Figure 2, G–I; Figure S1). We conclude that paraplegin-2 localizes
to the ER.
Topology of paraplegin-2 in the endoplasmic reticulum
In mitochondria, paraplegin is inserted via two TM domains in
the inner membrane, and exposes its catalytic domains in the
mitochondrial matrix. The orientation of integral membrane
proteins in the ER is not easily predicted and can depend on the
charges of the residues flanking the transmembrane regions. To
determine the topology of paraplegin-2 in the ER, we have used a
fluorescence protease protection assay (FPP) [18]. This assay uses
the restricted proteolytic accessibility of GFP-tagged transmem-
brane proteins to evaluate their intramembrane orientation.
Paraplegin-2-GFP was transfected in MEFs. As controls we also
transfected vectors encoding a soluble cytosolic GFP, a KDEL-
GFP (retained in the ER), and a GFP fused to the transmembrane
domain of cytochrome b5 (GFP-b5, exposed to the cytosolic side of
the ER) [17]. 24 hours after transfection, the cells were analyzed
using a live-imaging microscope. Digitonin was added at a
concentration of 10 mM to selectively permeabilize the cell
membrane. As expected, only the signal of freely diffusible
cytosolic GFP was lost completely. Cells were then washed with
an appropriate buffer followed by proteinase K treatment (50 mg/
ml). Proteins contained within a protected cell environment as the
lumen of the ER are unaffected by this treatment, while molecules
that span the membrane are affected depending on the position of
the GFP tag and their topology. We found that paraplegin-2-GFP
behaved as the intraluminal KDEL-GFP but unlike GFP-b5,
strongly indicating that the C-terminus of the protein, containing
the functional domains, is facing the lumen of the ER (Fig. 3).
Paraplegin-2 is endogenously synthesized in mouse
brain and retina
An important question is whether paraplegin-2 has any
physiological role, and to start to address this issue it is crucial
to demonstrate the endogenous existence of the protein.
Remarkably, the initial methionine of paraplegin-2 corresponds
to the first amino acid of the mature cleaved form of mitochondrial
paraplegin [19]. This strongly suggests that this protein may be
fully functional in the ER. However, it is impossible to distinguish
the two paraplegin isoforms by their electrophoretic motility on a
western blot (Fig. 4A).
We previously generated an Spg7 knock-out mouse model by
deleting exons 1 and 2 of the gene [15]. Exon 1b and the upstream
promoter region are instead intact in the targeted allele (Fig. 4B).
RT-PCR analysis on tissues derived from the knock out mouse
showed the presence of the alternative Spg7 transcript composed of
exon1b spliced directly to exon 3 (not shown). Thus our Spg7
model represents a specific knock out of the mitochondrial
paraplegin isoform. Tissues derived from this mouse represent
an ideal material to evaluate the endogenous presence of
paraplegin-2, since any protein detected can only derive from
the alternative transcript. To demonstrate that paraplegin-2 is
synthesized endogenously, we purified mitochondrial and micro-
somal fractions from the brain and retina of wild-type and Spg7
2/
2 mice. In the brain, a band of the expected molecular weight was
detected by the specific paraplegin antibody in both mitochondrial
and microsomal fractions in wild-type mice, although paraplegin
appeared to be more abundant than paraplegin-2 (Fig. 4C). In
Spg7
2/2 we detected some residual signal in the mitochondrial
fractions, owing to microsome retrocontamination, however the
amount of paraplegin detected in the microsomes was the same as
in wild-type animals. Notably, we did not detect microsomal
signals either for AFG3L2 or for the 70 kDa subunit of Complex
II, strongly indicating that this fraction is free from mitochondrial
contaminations (Figure 4C).
A Paraplegin Isoform in the Endoplasmic Reticulum
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mitochondrial and microsomal fractions from retina of wild-type
and Spg7 knock-out mice. Remarkably, a band of the correct
molecular weight was detected by the V61 antibody in microsomal
fractions purified from wild-type and knock-out mice (Fig. 4D).
These data strongly indicate that paraplegin-2 is expressed in vivo
in both mouse retina and brain, and that this isoform is still present
in the Spg7 knock-out mice.
Paraplegin-2 requires a molecular partner to form a high
molecular weight complex
AAA proteases must form assemblies to be functional, since the
activation of the ATPase domain occurs at the subunit interface
[20]. In mitochondria, paraplegin is part of the hexameric m-AAA
protease. Differently from AFG3L2 and AFG3L1, paraplegin is
unable to homo-oligomerize into a functional m-AAA protease
complex [11]. No isoforms of AFG3L2 and AFG3L1 are known to
Figure 1. Alternative splicing isoforms of the murine Spg7 gene. (A) Print-out from UCSC genome browser shows the existence of a complete
cDNA (BC055488, red arrow) and six different ESTs (red bar) starting from an upstream alternative exon for the murine Spg7 gene. These ESTs present
either ex1b-2 or ex1b-3 splicing and derives all from eye and retina libraries obtained at different developmental stages. (B) Schematic representation
of the two alternative Spg7 transcripts obtained from the Ensembl database, and of the two respective predicted protein products. MTS,
mitochondrial targeting sequence, TM, transmembrane domain, AAA, AAA domain, M41, M41 peptidase domain. (C) RT-PCR for the alternative Spg7
transcript on several mouse tissue cDNAs. On the top a scheme shows the position of the specific primers. The amplification products are detected as
a 210 bp long or a 320 bp long DNA fragments, depending on the splicing pattern. Control amplification was performed using oligonucleotides
specific for a housekeeping gene (GAPDH).
doi:10.1371/journal.pone.0036337.g001
Figure 2. Subcellular localisation of paraplegin-2. Immunofluorescence analysis of paraplegin and paraplegin-2 subcellular localisation in MEF
cells after transfection of the respective cDNAs. While paraplegin decorates mitochondria (A–C), paraplegin-2 loses the mitochondrial localisation (D–
F), but shows co-localisation with GFP-b5, a markers for the ER (G–I). Panel J shows an enlargement of the box in I. Paraplegin signal is detected using
a specific antibody (V61). Mitochondria are labelled by overexpressing a mitochondrially targeted GFP.
doi:10.1371/journal.pone.0036337.g002
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spliced mRNA for these genes and we excluded that these proteins
were present in microsomal preparations (Fig. 3C, and not shown).
To exclude that paraplegin-2 is able to homo-oligomerize, we
performed a gel filtration assay in COS7 cells overexpressing the
protein. As control, we also transfected the mitochondrial isoform.
Neither paraplegin nor paraplegin-2 formed high molecular
weight complexes when overexpressed alone (Figure 5A), suggest-
ing that the presence or the amount of an interacting partner is
limiting in this condition. As expected, co-expression of AFG3L2
with paraplegin, but not with paraplegin-2, induced the formation
of a high molecular weight complex (Figure 5B). These data
suggest that paraplegin-2 is unable to form a homo-oligomeric
complex in the ER without the presence or the right amount of a
specific interacting partner.
Discussion
In this study we characterise paraplegin-2, a novel protein
isoform encoded by an alternative splicing of the Spg7 gene. In
contrast to paraplegin, this isoform does not target to mitochon-
dria but to the ER, suggesting that AAA proteases may perform
additional functions outside mitochondria.
Several evidences point to a physiological relevance of
paraplegin-2. First, various ESTs and a complete cDNA
containing exon 1b have been isolated from different mouse
libraries. Consistently, we could amplify Spg7 mRNA containing
exon 1b in all mouse tissues we analysed. Second, the first
methionine of paraplegin-2 corresponds to the N-terminal residue
in mature mitochondrial paraplegin after consecutive cleavage by
the matrix metalloprotease and the m-AAA protease itself [19],
strongly suggesting that the function of paraplegin-2 might be
preserved. Finally, we show that paraplegin-2 accumulates
endogenously in microsomal fractions purified from mouse brain
and retina. All AAA
+ proteins form functional hexameric
complexes after homo-oligomerization or hetero-oligomerization
with a highly homologous protein [21,22]. In murine mitochon-
dria, paraplegin hetero-oligomerizes with AFG3L2 and/or
AFG3L1 to form the m-AAA protease, but it is unable to homo-
oligomerize into a stable complex [11]. Similarly, paraplegin-2
appears unable to form homo-oligomers after overexpression,
suggesting that it requires interaction with a molecular partner.
Since no evidence for alternative isoforms of AFG3L2 or AFG3L1
targeted to the ER was found, the identity of this potential
interactor is still unclear.
These data open up the possibility that AAA proteases might
function in the ER. In mitochondria, m-AAA proteases play key
roles in protein quality control of membrane proteins by degrading
misfolded proteins. A similar function could be envisioned for
AAA proteases in the ER. The primary mechanism of disposal of
misfolded proteins in the ER is the ER-associated degradation
Figure 3. Topology of paraplegin-2. (A) FPP assay on MEFs transfected with different GFP fusion proteins. After permeabilization with digitonin
(10 mM) for 1 min, all proteins, with the exception of a cytosolic GFP, retain their localisation in the ER. However, addition of 50 mg/ml proteinase K for
3 min disrupts the fluorescence pattern of cytosolic-exposed GFP-b5, but not that of KDEL-GFP and Paraplegin-2-GFP due to ER membrane
protection. (B) Decrease in fluorescence of different GFP-fusion proteins was quantified in live imaging, using a cooled camera driven by
METAMORPH software. Images were collected every 5 seconds for 10 minutes. Decrease in signal intensity after addition of proteinase K is visible, as
expected, for GFP-b5, but not for KDEL-GFP, and paraplegin-2-GFP.
doi:10.1371/journal.pone.0036337.g003
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26S proteasome [23]. How soluble ERAD substrates are retro-
translocated to the cytosol is well known, while much less clear is
the mechanism by which polytopic, integral membrane substrates
are delivered to the ubiquitin-conjugation system and the
proteasome [24]. In some cases these substrates are recognized
directly by E3 ubiquitin ligases [25,26], but the presence of
additional systems cannot be excluded. Another possibility is that
similar to its mitochondrial counterpart, a putative AAA protease
in the ER might be implicated in critical biogenesis steps, by
promoting the maturation of specific substrates. Future studies will
be required to address these issues, by identifying the partner of
paraplegin-2 in the complex and possible interactors/substrates.
The tissue-specific expression of paraplegin-2 makes this task very
challenging. In fact, detection of paraplegin-2 in retina microsomal
fraction is in agreement with the origin of all the cDNA clones
present in the databases, suggesting that paraplegin-2 might play a
tissue-specific role in the retina.
Our data also show that the Spg7
2/2 mouse should be regarded
as an isoform-specific knock-out model, leading to the selective
lack of paraplegin from mitochondria. The phenotype of these
mice strongly argues for a predominant role of mitochondrial
paraplegin in HSP. Spg7
2/2 mice recapitulate all the crucial
features of the human disease, including the motor deficit and the
progressive axonopathy restricted to long central and peripheral
axons, and their phenotype could be rescued by reintroduction of
the mitochondrial protein [15,16]. However, an important
question elicited by our findings is whether a fraction of paraplegin
may exist outside mitochondria also in humans and contribute to
some pathogenic aspects of HSP. Evidence for human ESTs
containing alternative first exons for SPG7 can be found in public
databases (Fig. S2, Table S2). Again, these transcripts are
predicted to encode isoforms of human paraplegin lacking the
mitochondrial targeting sequence. Further analyses are needed to
confirm these predictions experimentally. Most SPG7 mutations
identified in HSP patients can potentially affect all isoforms,
however two pathogenic mutations, one missense (A10S) and one
affecting the first methionine, have been found in exon 1 [7,27],
arguing for the fact that it is sufficient to affect mitochondrial
paraplegin to induce HSP, similarly to what occur in the mouse.
However, a role for an ER localized paraplegin in human disease
appears particularly intriguing, since the number of HSP proteins
residing in the ER is becoming notable. At least three HSP
associated proteins, spastin, atlastin-1, and REEP1 are involved in
ER membrane shaping and modelling events and have been
shown to interact in the ER membrane [28,29]. This is an
important subgroup, as mutations in the genes encoding these
proteins cause up to 60% of HSP cases [28]. Other HSP proteins,
Figure 4. Paraplegin-2 is endogenously expressed in microsomal fractions. (A) Western blot analysis of overexpressed paraplegin or
paraplegin-2. Note that paraplegin-2 has the same electrophoretic motility as the mature form of paraplegin. Mitochondrial extracts are loaded as a
control. p, precursor; m, mature form. (B) Scheme of the targeted allele in Spg7
2/2 mice. (C) Western blot analysis of mitochondrial and microsomal
fractions obtained from adult control and Spg7
2/2 mouse brains. Enrichment of mitochondria and microsomes in the fraction were evaluated by
using antibodies against 70 kDa subunit of Complex II and calnexin, respectively. A protein with the same molecular weight of paraplegin in the
microsomal fractions is recognized by the specific paraplegin antibody. Note that 100 mg of microsomes were loaded versus 30 mg of mitochondria,
and that blots were developed using ECL plus to reveal the bands in the microsomes. The paraplegin band in the mitochondrial fraction of Spg7
2/2
mice is likely a retrocontamination of mitochondria with microsomes. (D) Western blot analysis of mitochondrial and microsomal fractions obtained
from retina of Spg7
2/2 and control mice using the specific paraplegin antibody. Pooled retinas from 15 Spg7
2/2 mice and 12 control mice were used
for this experiment. The enrichment of mitochondria and microsomes in the fractions was evaluated by antibodies against NDUFB6 (17 kDa subunit
of Complex I) and calnexin, respectively.
doi:10.1371/journal.pone.0036337.g004
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appear to accumulate, and to induce ER stress and subsequent
apoptotic death [30,31]. Future studies are required to address the
function of paraplegin-2 and its potential relevance in neurode-
generation.
Materials and Methods
DNA constructs
The BC055488 clone was ordered from ImaGenes (IR-
AKp961N10120Q). Generation of paraplegin-2-GFP construct
was obtained by amplification of paraplegin-2 cDNA from
BC055488 clone using these oligonucleotides: FW 59-TTCTCGA-
GAACACCTCAAGGATGAAGCAG-39, REV 59-TTGGATC-
CCGGGAGCCGGAGCCTCCTC-39.
The amplified cDNA was then cloned 59 and in-frame to the
GFP cDNA in pEGFP Nu2 vector (Clontech). GFP-b5 [32] and
KDEL-GFP were kind gift from Nica Borgese, mito-GFP was a
kind gift from K. Mihara [33], Atlastin-1-GFP was a kind gift from
Andrea Daga.
RT-PCR
Total RNA was isolated from mouse tissues using TRIzol Kit
(Invitrogen) and retro-transcribed into cDNA using SuperScript
kit (Invitrogen). Amplification of the alternative splicing isoform of
Spg7 was obtained by RT-PCR using these oligonucleotides: Ex1-b
59-GAGGAAGCCAGCCACGAGGTG-39; Ex4 59-GAGGGA-
GTTCAGCAGGCTCATG-39.
For GAPDH amplification we used these oligonucleotides: FW
59-TGGTGAAGGTCGGTGTGAAC-39, REV 59-CAGTGAT-
GGCATGGACTGTG -39.
Immunofluorescence analysis and live imaging
microscopy
Establishment of MEFs was already described [34]. NSC34 cells
were obtained from N. Cashman [35]. Cell lines were cultured in
DMEM with 10% Fetalclone III serum (Hyclone) or 5% defined
FBS, respectively, and transiently transfected for 24 hours using
Lipofectamine2000 (Invitrogen). Immunofluorescence assays were
performed as previously reported [36]. Confocal microscopy was
performed with a Bio-Rad (Hercules, CA, USA) Radiance 2100
confocal microscope at 102461024-pixel resolution. To perform
live imaging FPP assay, cultures were transferred to a live cell
imaging workstation composed of an inverted microscope (Nikon
Eclipse TE2000-S+BD CARV II, Nikon, Melville, NY, USA), a
heated (37uC) chamber and a Nikon Plan Apo VC 100X/1.40 oil
objective. Cells were incubated with digitonin 10 mM for 1 min
and followed by addition of proteinase K 50 mg/ml. Images were
collected every 5 seconds for 10 min using a cooled camera
(QUANTEM 512 SC) driven by METAMORPH software
(Molecular Devices Ltd, Downingtown, PA, USA). The same
software was used for fluorescence quantification measurements.
Subcellular fractionation and gel filtration assay
All animal procedures were conducted in accordance with
European (EU directive 86/609/EEC), national (TierSchG), and
institutional guidelines and protocols, and were approved by local
governmental authorities (Landesamt fu ¨r Natur, Umwelt und
Verbraucherschutz Nordrhein-Westfalen) under the license 87–
51.04.2010.A219.
For mitochondria and microsomes purification, mouse brains
and retinas were homogenized (10 strokes) in 10 volumes/g of wet
tissue isolation buffer (220 mM D-Mannitol, 70 mM Sucrose,
20 mM Hepes, 1 mM EDTA and 0.1% w/v BSA, pH=7.2) using
a glass/Teflon pestle. The crude homogenate was sequentially
centrifuged at 500 g and 1,000 g for 10 min and then the
supernatant was centrifuged again at 8,000 g for 10 min for
mitochondria precipitation. The crude mitochondrial fraction was
resuspended in 6 volumes/g of wet tissue of isolation buffer and
purified again with sequential centrifugation steps of 10 min each
at 500 g, 1,000 g and 8,000 g. The supernatant fraction was
instead cleaned by two centrifugations at 20,000 g for 10 min,
before performing microsomal precipitation at 150,000 g for
2 hours. Both mitochondrial and microsomal fractions were
resuspended in RIPA buffer (50 mM Tris-HCl, 1% w/v NP-40,
0.25% w/v Sodium Deoxicolate, 150 mM NaCl and 1 mM
EDTA, pH=7.4) for SDS-PAGE experiments and in GF buffer
(30 mM Tris-HCl pH=7.4, 10 mM Mg-acetate, 150 mM K-
acetate pH=7.4, 1 mM PMSF and 5 mM ATP) for gel filtration
assays.
Gel filtration analyses were performed as previously reported
[11].
Antibodies
Specific rabbit polyclonal antibodies against mouse paraplegin
and AFG3L2 were previously described [15,34]. Mouse mono-
clonal antibodies against a-70 kDa subunit of Complex II and
anti- NDUFB6 (17 kDa subunit of Complex I) were purchased
from Invitrogen; rabbit polyclonal anti-calnexin antibody was
purchased from Stressgen.
Figure 5. Paraplegin-2 forms high-molecular weight complex-
es. (A) Gel filtration analysis of paraplegin and paraplegin-2 high
molecular weight complexes. Extracts obtained from COS7 cells
transfected with paraplegin and paraplegin-2 cDNAs were fractionated
by Superose 6 sizing chromatography. Eluate fractions were TCA
precipitated and analysed by SDS-PAGE and immunoblotting using V61
a-paraplegin polyclonal antibodies. Overexpression of paraplegin or
paraplegin-2 alone does not lead to the formation of a high molecular
weight complex. Some aggregates are detected in fractions corre-
sponding to the exclusion volume (E). In the case of paraplegin these
aggregates are specific for the uncleaved precursor (p) that accumu-
lates since cleavage of paraplegin depends on the m-AAA protease
itself [19]. (B) When AFG3L2 is co-expressed, the formation of a high
molecular weight complex becomes evident for paraplegin (*), but not
for paraplegin-2. Note that paraplegin is now completely cleaved. The
following marker proteins were used for calibration: 1, Tyroglobulin
(660 kDa); 2, Ferritin (440 kDa); 3, Alcohol Dehydrogenase (150 kDa); 4,
Carbonic anhydrase (29 kDa), E indicates the exclusion volume of the
column. p, precursor; m, mature form.
doi:10.1371/journal.pone.0036337.g005
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Figure S1 Paraplegin-2 localises to the endoplasmic
reticulum in NSC34 cells. Immunofluorescence analysis of
paraplegin-2 subcellular localisation in NSC34 cells after co-
transfection with constructs encoding mCherry-seipin or atlastin1-
myc-GFP. The latter proteins are known to localise to the
endoplasmic reticulum. Paraplegin signal is detected using a
specific antibody (V61).
(TIF)
Figure S2 Putative human alternative SPG7 ESTs.
Schematic view of the human SPG7 transcripts and of two ESTs
containing putative alternative first exons (only the first exons are
shown).
(TIF)
Table S1 Murine Spg7 cDNAs and ESTs containing exon1b.
(DOCX)
Table S2 Human SPG7 ESTs containing alternative first exons.
(DOCX)
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